Navigation Links
Experts from Penn's School of Medicine to present at ACC Annual Scientific Session
Date:3/30/2008

Penn experts will present research findings that could come to define new standards of cardiovascular diagnostics and care at this weekends conference of the American College of Cardiology, the foremost professional society representing heart specialists throughout the world. These experts will gather beginning this weekend in Chicago to present and discuss the latest advances in cardiovascular medicine, science and education.

To arrange interviews with any of these presenters or other Penn physicians who will be in attendance, please call 215-200-2313, or email holly.auer@uphs.upenn.edu. All research results are embargoed until the time they are presented during the conference.

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients with Coronary Heart Disease or Risk Equivalent

Emile R. Mohler, MD, Director of Vascular Medicine and Associate Professor of Medicine
10 a.m., Sunday, March 30

Dr. Mohler will present results of a trial that may herald a new class of medications to prevent heart attack and stroke. Researchers at Penn and several other sites around the world studied the safety and efficacy of the drug darapladib (manufactured by GlaxoSmithKline) on Lp-PLA, an enzyme associated with inflammatory activity and increased risk for heart attack and stroke.

The drug was tested among patients already taking a cholesterol-lowering statin drug. After 12 weeks on a daily regimen of 160 mg of darapladib, blood tests revealed a decrease in two important circulating biomarkers, suggesting a possible reduction in systemic inflammatory burden.

While the drug doesnt necessarily act to shrink plaque, Mohler says the research suggests that darapladib may reduce plaque inflammation and therefore lower rates of clot formation and heart attacks among patients with coronary heart disease.

These findings will be published in an upcoming issue of JACC, the Journal of the American College of Cardiology.


Under-Referral of Women for Atrial Fibrillation Ablation: Can This Be Explained by Gender Differences in Outcome?

Andrea M. Russo, MD, Electrophysiology Laboratory Director and Clinical Associate Professor of Medicine
10 a.m., Sunday, March 30

Dr. Russo and her colleagues from the division of cardiovascular medicine at Penn will present research on disparities in treatment of women suffering atrial fibrillation, one of the most common abnormal heart rhythms.

Although women represent more than half of patients with this serious rhythm problem, they are less likely to be referred for atrial fibrillation ablation a therapy that uses radiofrequency energy to cauterize the heart tissue around each pulmonary vein to keep abnormal electrical signals from reaching the rest of the heart and triggering the faulty rhythm than men.

Russo studied 1,165 women and men who underwent ablation at Penn and found that both groups had similar arrhythmia control at 24 months after the procedure (84 percent of women and 89 percent of men), suggesting that more women should be referred for ablation therapy.


Women Face Higher Risk for Decline in Left Ventricular Ejection Fraction Following Orthotopic Liver Transplant

James N. Kirkpatrick, MD, Assistant Professor of Medicine
10 a.m., Tuesday, April 1

Chronic liver disease patients often have low systemic vascular resistance that causes low blood pressure before liver transplant, but after receiving a new liver, they may suffer post-operative heart problems that leave the left ventricle unable to pump out an adequate amount of blood. This situation puts patients at a greater risk of organ failure and death.

Dr. Kirkpatrick and his colleagues studied 80 patients who received an orthotopic liver transplant the procedure in which the patients native liver is removed and replaced with a donor organ in the same spot to determine who would be more likely to suffer post-transplant complications of the left ventricle.

Researchers found that female patients were more likely to exhibit a left ventricular ejection fraction depression following transplant, with 36.7 percent of women suffering the complication, compared to 16 percent of men.

Kirkpatrick believes that careful pre-operative ventricular assessment may help identify patients who could benefit from careful monitoring of blood pressure, heart rate and volume status, and, possibly, serial echocardiograms. Some of these patients may benefit from aggressive treatment with medications like ACE-inhibitors and beta blockers. The Penn researchers plan to test newer echocardiographic techniques before and after transplant to refine ways to identify these patients.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Infant formula must contain DHA omega-3 and AA omega-6, say international experts
2. Teen Driving Experts at The Childrens Hospital of Philadelphia Support New Recommendations From the New Jersey Teen Driver Study Commission
3. NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports
4. ID, HIV experts urge more resources for TB
5. CMS Approves Home Sleep Testing for Diagnosis of OSA; AASM Experts Available for Comment
6. New England Area Fertility Experts Issue Call for Ethnic Egg Donors
7. Experts call for community mobilization to curb youth violence
8. The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal
9. Experts will analyze the nutrition and health relationship from pregnancy to adolescence
10. Spiritual Health Experts Speak at Chaplains Conference in Pittsburgh March 8-12
11. Experts Delve Into Issues of HPV Vaccination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... 21st century approach to infusing high speed technology into the fabric of an ... to the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Medic-CE ... EMS and firefighting professionals, has released four new continuing education courses as part ... taught live in an online classroom and meet the requirements of the National ...
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, luggage and ... to Cradle Product Design Challenge , the Cradle to Cradle Products Innovation Institute ... design challenges scheduled to run through early 2018. The challenges are presented by the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein ... to families and business professionals throughout central Colorado, is joining local nonprofit Aurora ... The Aurora Warms The Night organization is committed to breaking the cycle of ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... visualize, detect, and eliminate cyber threats in real-time, today announced a strategic partnership ... headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become a ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  CSSi, the global ... the clinical research industry, will exhibit at the 8 ... Executives (SCOPE 2017), taking place from Tuesday, January 24 ... Miami in Miami, FL. ... proprietary technology platform, SmartStudy™ EMR, which provides a revolutionary ...
(Date:1/17/2017)... New York , January 17, 2017 ... Derivatives (Cinnamic Acid, Benzoic Acid, Sodium Benzoate, Benzyl Alcohol and Others) ... 2016-2024., According to the report, the global benzaldehyde derivative market ... projected to reach US$ 2.14 Bn by 2024, expanding at a ... ...
(Date:1/17/2017)...  Bayer today announced the appointment of Dr. Carsten ... Americas, comprising the United States , ... . In this role, Dr. Brunn will report to ... of Bayer AG and President of the Pharmaceutical division. ... the pharmaceutical industry and I,m delighted to have him lead ...
Breaking Medicine Technology: